Other Events ·
NervGen restates financials after non-cash valuation errors reduce reported stock-based compensation and warrant liabilities
NGENNervgen Pharma Corp.
On September 25, 2026, NervGen Pharma Corp.'s audit committee concluded that previously issued audited financial statements for years ended December 31, 2024 and 2025, as well as unaudited interim information for the quarter ended June 30, 2026, should no longer be relied upon. The company identified non-cash valuation errors in accounting for stock options and derivative warrant liabilities, which reduced previously reported stock-based compensation expense and warrant liabilities. NervGen intends to restate these affected financials via amendments to its Form 40-F and Form 6-K filings. These adjustments do not impact the company's cash position, cash flow, or liquidity. The company operates in the biopharmaceutical industry, focusing on the development of gene therapies.